Last reviewed · How we verify
Alternative Treatment Group
Alternative Treatment Group, marketed by Gregory Gilot, holds a position in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging its established patient base and brand recognition. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | Alternative Treatment Group |
|---|---|
| Also known as | Repair cannot be accomplished |
| Sponsor | Gregory Gilot |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- NEUROCUPLE™ as an Opioid Alternative Following Total Knee Arthroplasty (NA)
- Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy (NA)
- Autologous Whole Blood Therapy in Chronic Idiopathic Urticaria Patients. (PHASE3)
- Time Pressure Motor Training With Step Square Exercise on Stroke Patients (NA)
- MRI Guided Management of Occlusive Peripheral Arterial Disease
- Smoking Harm Reduction Using E-cigarettes and Cytisine (NA)
- OPEN Versus InTact Capsule Proton Pump Inhibitors for the Treatment of Marginal Ulcers (PHASE4)
- RESCUE: Discontinuation of GLP-1
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alternative Treatment Group CI brief — competitive landscape report
- Alternative Treatment Group updates RSS · CI watch RSS
- Gregory Gilot portfolio CI